Emergent BioSolutions’ COVID-HIG to be part of NIH trial
Hyperimmune intravenous immunoglobulin products are obtained from plasma of Covid-19-recovered individuals. Credit: Gerd Altmann from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more